These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21978946)

  • 1. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
    Kaku T; Hitaka T; Ojida A; Matsunaga N; Adachi M; Tanaka T; Hara T; Yamaoka M; Kusaka M; Okuda T; Asahi S; Furuya S; Tasaka A
    Bioorg Med Chem; 2011 Nov; 19(21):6383-99. PubMed ID: 21978946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
    Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
    J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 17,20-lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors.
    Kaku T; Matsunaga N; Ojida A; Tanaka T; Hara T; Yamaoka M; Kusaka M; Tasaka A
    Bioorg Med Chem; 2011 Mar; 19(5):1751-70. PubMed ID: 21316976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
    Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
    Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure-activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors.
    Kaku T; Tsujimoto S; Matsunaga N; Tanaka T; Hara T; Yamaoka M; Kusaka M; Tasaka A
    Bioorg Med Chem; 2011 Apr; 19(7):2428-42. PubMed ID: 21429754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
    Hu Q; Negri M; Jahn-Hoffmann K; Zhuang Y; Olgen S; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
    Bioorg Med Chem; 2008 Aug; 16(16):7715-27. PubMed ID: 18674917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
    Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
    J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is still there a place for orteronel in management of prostate cancer? Data from a literature based meta-analysis of randomized trials.
    Roviello G; Pacifico C; Chiriacò G; Generali D
    Crit Rev Oncol Hematol; 2017 May; 113():18-21. PubMed ID: 28427507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of phenyl alkyl imidazole-based compounds as potent inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
    Owen CP; Shahid I; Olusanjo MS; Patel CH; Dhanani S; Ahmed S
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):117-27. PubMed ID: 18620055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM; Abbott DH
    J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
    Yamaoka M; Hara T; Araki H; Kaku T; Hitaka T; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2013 Nov; 138():298-306. PubMed ID: 23856460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q; He C; Lao K; Luo G; You Q; Xiang H
    Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
    Zhu H; Garcia JA
    Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors.
    Matsunaga N; Kaku T; Ojida A; Tanaka T; Hara T; Yamaoka M; Kusaka M; Tasaka A
    Bioorg Med Chem; 2004 Aug; 12(16):4313-36. PubMed ID: 15265485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)).
    Owen CP; Dhanani S; Patel CH; Shahid I; Ahmed S
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4011-5. PubMed ID: 16750362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
    Zainuddin M; Vinod AB; Gurav SD; Police A; Kumar A; Mithra C; Dewang P; Kethiri RR; Mullangi R
    Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):1-7. PubMed ID: 25297456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
    Petrunak EM; Rogers SA; Aubé J; Scott EE
    Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.